Latest news with #WalgreensBootsAlliance
Forbes
17 hours ago
- Business
- Forbes
Best Buy Appoints Neal Sample As New Technology Chief To Boost Digital Strategy
A Best Buy retail store Best Buy has named Neal Sample as its new chief digital and technology officer, bringing in a seasoned executive with a wide-ranging background to accelerate the company's digital transformation. He will start on July 14, 2025 Sample most recently served as executive vice president and CIO at Walgreens Boots Alliance, where he held the role for just under two years. That was proceeded by the CIO post at Northwestern Mutual and being promoted from CIO to COO of Express Scripts prior to its purchase by Cigna. He is also a past Group President of Enterprise Growth at American Express. Sample also has a PhD in Computer Science from Stanford University. Neal Sample He succeeds Brian Tilzer, who joined Best Buy in 2018 and carried the title of Chief Digital, Analytics, and Technology Officer of the company. He joined Best Buy after having been the Chief Digital Officer of CVS Health. In a note to employees, CEO Corie Barry praised Sample's breadth of experience across both traditional and tech-driven organizations. 'Neal has a unique background, having spent time in legacy businesses as well as in high-tech and digitally native companies,' Barry wrote, the latter referring to Sample's stints at the likes of eBay and Yahoo!. She also noted that his leadership approach is expected to help Best Buy move 'with greater speed, clarity and conviction.' 'I'm thrilled to join Best Buy at such a pivotal moment,' Sample underscored. 'It's a brand I've long admired with a strong foundation and a clear commitment to innovation. I'm excited to partner with the team to accelerate digital initiative and deliver increasing value to customers.' The leadership change comes as Best Buy works to sharpen its digital edge in an increasingly competitive consumer electronics landscape. Peter High is President of Metis Strategy, a business and IT advisory firm. He has written three bestselling books, including his latest Getting to Nimble. He also moderates the Technovation podcast series and speaks at conferences around the world. Follow him on Twitter @PeterAHigh.
Yahoo
2 days ago
- Business
- Yahoo
Compared to Estimates, Walgreens (WBA) Q3 Earnings: A Look at Key Metrics
Walgreens Boots Alliance (WBA) reported $38.99 billion in revenue for the quarter ended May 2025, representing a year-over-year increase of 7.3%. EPS of $0.38 for the same period compares to $0.63 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $36.61 billion, representing a surprise of +6.49%. The company delivered an EPS surprise of +11.76%, with the consensus EPS estimate being $0.34. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- U.S. Retail Pharmacy: $30.72 billion compared to the $28.76 billion average estimate based on four analysts. The reported number represents a change of +7.8% year over year. Revenues- U.S. Healthcare: $2.10 billion versus $2.17 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change. Revenues- International: $6.17 billion versus the four-analyst average estimate of $5.74 billion. The reported number represents a year-over-year change of +7.8%. Adjusted operating income (loss)- U.S. Retail Pharmacy: $350 million versus the two-analyst average estimate of $113.67 million. Adjusted operating income (loss)- Corporate and Other: -$60 million versus the two-analyst average estimate of -$52.50 million. Adjusted operating income (loss)- U.S. Healthcare: $54 million versus the two-analyst average estimate of $72.85 million. Adjusted operating income (loss)- International: $214 million versus $196.39 million estimated by two analysts on average. View all Key Company Metrics for Walgreens here>>>Shares of Walgreens have returned +1.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Walgreens Q3 Earnings Top Estimates, Stock Up, Gross Margin Declines
Walgreens Boots Alliance, Inc. WBA delivered adjusted earnings per share (EPS) of 38 cents in the third quarter of fiscal 2025, down 39.7% from the year-ago quarter's figure (down 39.6% at the constant exchange rate or CER). However, the figure topped the Zacks Consensus Estimate by 11.76%. GAAP loss per share for the third quarter was 20 cents compared to the year-ago quarter's EPS of 40 cents. Walgreens Boots recorded total sales of $38.99 billion in the fiscal third quarter, up 7.2% year over year and 6.9% at CER. The top line also surpassed the Zacks Consensus Estimate by 6.5%. Following the announcement, Walgreens shares rose 0.9% in the pre-market session today. The company currently operates its business through three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare. The segment's sales increased 7.8% year over year to $30.7 billion in the fiscal third quarter. Comparable sales jumped 10.3% from the year-ago quarter's levels. Pharmacy sales were up 11.8% from the year-ago quarter's figures, and comparable pharmacy sales increased 14.6%, each benefiting from higher branded drug inflation and mix impacts. Retail sales fell 5.3%, and comparable retail sales were down 2.4% year over year due to weaker sales in grocery and household, health and wellness, and beauty. Revenues in the International division rose 7.8% on a year-over-year basis and increased 5.9% at CER to $6.2 billion in the fiscal third quarter. In Germany, wholesale business sales increased 6.8% in the fiscal third quarter. Walgreens Boots Alliance, Inc. price-consensus-eps-surprise-chart | Walgreens Boots Alliance, Inc. Quote Boots UK sales rose 5% year over year. Its comparable retail sales advanced 6%. Further, Boots UK comparable pharmacy sales increased 5.4% year over year at CER. U.S. Healthcare reported fiscal third-quarter revenues of $2.1 billion. Within the segment, VillageMD sales decreased 6.5% year over year, while CareCentrix and Shields sales increased 11.6% and 24.8%, respectively. The gross profit in the reported quarter increased 075% year over year to $6.51 billion despite an 8.7% rise in the cost of sales. The gross margin contracted 108 basis points to 16.7%. Selling, general and administrative (SG&A) expenses increased 1.6% year over year to $6.49 billion. The company reported an adjusted operating profit of $13 million for the quarter compared with the year-ago period's profit of $66 million. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Walgreens Boots exited the third quarter of fiscal 2025 with cash and cash equivalents of $766 million compared with $702 million at the second quarter-end. The total debt was $7.37 billion compared with $8.01 billion at the end of the fiscal second quarter. The cumulative cash used by operating activities at the end of the third quarter of fiscal 2025 was $245 million compared with the year-ago period's outflow of $314 million. On March 6, 2025, WBA signed a definitive agreement to be acquired by entities affiliated with Sycamore Partners. The merger is expected to close in the third or fourth quarter of the calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing. Following the close of the transaction, WBA will become a private company, and its common stock will be delisted from the Nasdaq stock market. In light of the pending transaction, the company has withdrawn issuing fiscal 2025 guidance. Furthermore, Walgreens' previously issued guidance for the full year is no longer in effect. Walgreens Boots ended the third quarter of fiscal 2025 with better-than-expected earnings and revenues. The results reflected continued improvement in the U.S. Healthcare segment and gains from the cost savings initiatives. At the same time, U.S. front-end sales remained soft. Walgreens Boots' bottom line was down on a year-over-year basis. A contraction of the gross margin in the quarter is discouraging. WBA management remains committed to its turnaround plan, which will require time and a disciplined, balanced approach to align future cash needs with necessary investments in a changing pharmacy and retail environment. Walgreens Boots currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Veeva Systems VEEV, Intuitive Surgical ISRG and Integer Holdings ITGR. Veeva Systems, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. You can see the complete list of today's Zacks #1 Rank stocks here. VEEV has an estimated long-term earnings growth rate of 23.3% compared to the industry's 19.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 10%. Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2025 adjusted EPS of $1.81, exceeding the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. ISRG has an estimated long-term earnings growth rate of 15.1% compared to the industry's 14.4% growth. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Integer Holdings, carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 1.8%. Revenues of $414.8 million topped the Zacks Consensus Estimate by 0.4%. ITGR has a long-term earnings growth rate of 18.4% compared to the industry's 14.4% growth. The company's earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Walgreens (NASDAQ:WBA) Exceeds Q2 Expectations
Pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 7.2% year on year to $38.99 billion. Its non-GAAP profit of $0.38 per share was 11.3% above analysts' consensus estimates. Is now the time to buy Walgreens? Find out in our full research report. "On March 6, 2025, WBA entered into a definitive agreement to be acquired by entities affiliated with Sycamore Partners. The merger is currently expected to close in the third or fourth quarter of calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing. Upon completion of the transaction, WBA common stock will no longer be listed on the Nasdaq Stock Market, and WBA will become a private company." Revenue: $38.99 billion vs analyst estimates of $36.59 billion (7.2% year-on-year growth, 6.5% beat) Adjusted EPS: $0.38 vs analyst estimates of $0.34 (11.3% beat) Operating Margin: 0.1%, in line with the same quarter last year Free Cash Flow Margin: 0.9%, similar to the same quarter last year Market Capitalization: $9.78 billion Primarily offering prescription medicine, health, and beauty products, Walgreens Boots Alliance (NASDAQ:WBA) is a pharmacy chain formed through the 2014 major merger of American company Walgreens and European company Alliance Boots. A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. With $154.6 billion in revenue over the past 12 months, Walgreens is a behemoth in the consumer retail sector and benefits from economies of scale, giving it an edge in distribution. This also enables it to gain more leverage on its fixed costs than smaller competitors and the flexibility to offer lower prices. However, its scale is a double-edged sword because it's harder to find incremental growth when you've penetrated most of the market. To expand meaningfully, Walgreens likely needs to tweak its prices or enter new markets. As you can see below, Walgreens grew its sales at a sluggish 3.8% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts). This shows it failed to generate demand in any major way and is a rough starting point for our analysis. This quarter, Walgreens reported year-on-year revenue growth of 7.2%, and its $38.99 billion of revenue exceeded Wall Street's estimates by 6.5%. Looking ahead, sell-side analysts expect revenue to decline by 1.6% over the next 12 months, a deceleration versus the last six years. This projection is underwhelming and indicates its products will see some demand headwinds. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Same-store sales is a key performance indicator used to measure organic growth at brick-and-mortar shops for at least a year. Walgreens has been one of the most successful retailers over the last two years thanks to skyrocketing demand within its existing locations. On average, the company has posted exceptional year-on-year same-store sales growth of 6.7%. Note that Walgreens reports its same-store sales intermittently, so some data points are missing in the chart below. We were impressed by how significantly Walgreens blew past analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. No guidance was provided due to the impending acquisition of the company. Zooming out, we think this was a solid quarter. The stock remained flat at $11.40 immediately after reporting. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Walgreens Boots Alliance (WBA) Q3 Earnings and Revenues Beat Estimates
Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.76%. A quarter ago, it was expected that this largest U.S. drugstore chain would post earnings of $0.53 per share when it actually produced earnings of $0.63, delivering a surprise of +18.87%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Walgreens, which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, posted revenues of $38.99 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 6.49%. This compares to year-ago revenues of $36.35 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Walgreens shares have added about 21.2% since the beginning of the year versus the S&P 500's gain of 3.6%. While Walgreens has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Walgreens was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $36.98 billion in revenues for the coming quarter and $1.69 on $151.46 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Pharmacies and Drug Stores is currently in the top 2% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the broader Zacks Retail-Wholesale sector, Genuine Parts (GPC), has yet to report results for the quarter ended June 2025. This auto and industrial parts distributor is expected to post quarterly earnings of $2.08 per share in its upcoming report, which represents a year-over-year change of -14.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Genuine Parts' revenues are expected to be $6.11 billion, up 2.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report Genuine Parts Company (GPC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
